Modular Medical (NASDAQ: MODD) has announced the completion of an extensive market research study conducted with cardiometabolic patient insights company closely held Thrivable to evaluate perceptions of Modular Medical’s Pivot Insulin Delivery System across a diverse sample of more than 540 Type 1 and Type 2 Diabetes participants.
The study enrolled both multiple daily injection users as well as individuals who transitioned to insulin pump therapy. According to Modular, one of the most compelling findings from the research was the widespread desire for a simpler insulin delivery experience.
In a statement, Jeb Besser, CEO of Modular, commented, “This research validates a fundamental belief that has guided the development of Pivot from the beginning: millions of people who use insulin are looking for a simpler path to insulin delivery. The findings clearly demonstrate that treatment burden remains high, cost and complexity continue to be barriers to pump adoption, and patients are actively seeking simplified alternatives that fit more naturally into daily life. The insights generated through this collaboration with Thrivable will help guide our patient engagement, educational initiatives, and commercialization planning as we prepare to bring Pivot to the people who can benefit most from it.”
